Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

APPROVED FOR ALL STAGES OF APC1,2

George - a patient with biochemical-failure advanced prostate cancer

GEORGE, 72

BIOCHEMICAL FAILURE*

GEORGE, 72

BIOCHEMICAL FAILURE*

PATIENT HISTORY AND DIAGNOSIS

  • Radical prostatectomy 4 years ago
  • Stage T3a, N0, M0
  • Gleason score: 7 (4+3)
  • Presurgery PSA was 8 ng/mL
  • PSA undetectable after surgery

PERSONAL AND FAMILY HISTORY

  • Retired systems analyst
  • He and his wife are proactive about their health

≈2 Years After Surgery

  • PSA was 5 ng/mL
  • Patient refused possible treatment

PRESENT VISIT (≈4 YEARS AFTER DIAGNOSIS)

  • Previous visit 6 months ago, PSA of 5 ng/mL
  • Current visit PSA is 10 ng/mL (doubled in 6 months)
  • Negative bone scan
  • Using 2 pads per day

Hypothetical patient based on patient types studied in clinical trials. The pivotal CS21 study included men aged ≥18 years with histologically confirmed adenocarcinoma of the prostate (all stages), for whom endocrine treatment was indicated (except for neoadjuvant therapy).1

George - a patient with biochemical-failure advanced prostate cancer

Abbreviations: APC = advanced prostate cancer; PSA = prostate-specific antigen.

Monthly Matters

Help make the most of your patient's treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

I like the regularity of the monthly shot and the chance it gives me 
to build a relationship with my treatment team.
Actual physician quote

REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.